Independent Board Chairman

Donald Santel served as Executive Chairman of Adicet Bio, Inc., a private allogeneic cell therapy oncology company, from October 2017 through its business combination with resTORbio, Inc. in September 2020. From March 2018 through April 2019, Mr. Santel also served as Adicet Bio’s interim Chief Executive Officer. He previously served as Chief Executive Officer of Hyperion Therapeutics, a public biopharmaceutical company, from June 2008 until the sale of the company to Horizon Pharma in May 2015 and was a member of Hyperion’s board of directors from March 2007 through the company’s sale. Previously, Mr. Santel was a co-founder, a member of the board of directors, and the Chief Executive Officer of CoTherix, Inc., from January 2000 through its sale to Actelion in January 2007. Prior to joining CoTherix, Mr. Santel was employed by several medical device companies, including Cardiac Pathways Corporation (acquired by Boston Scientific) and Medtronic, Inc. Mr. Santel has served as chairman and independent director of Ocelot Bio, Inc., a private biopharmaceutical company, since June 2021, and as chairperson of Oyster Point Pharma, Inc., a publicly traded biopharmaceutical company, since July 2021. Mr. Santel has also served as an independent director of Consonance-HFW Acquisition Corporation from November 2020 through the completion of its business combination with Surrozen, Inc., in August 2021. Mr. Santel previously served on the board of directors and the audit and compensation committees of Anthera Pharmaceuticals, Inc., and as a director of ChemGenex Pharmaceuticals, Inc.

Tentarix Director, Managing Partner at Samsara BioCapital

Srini Akkaraju is a founder of Tentarix and also serves as a Director of Seattle Genetics, Intercept Pharmaceuticals, Versartis and aTyr Pharma. Previously, he served as a director on the boards of Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma, and Amarin Corporation. Srini founded Samsara BioCapital in 2016. His vast experience in the industry includes being a general partner at Sofinnova Ventures, Managing Director of New Leaf Ventures, Managing Director of Panorama Capital, partner at J.P. Morgan and senior management at Genentech.

Srini holds a B.S. in Biochemistry and Computer Science from Rice University, and an M.D. and a Ph.D. in Immunology from Stanford University.

Tentarix Director, Managing Director at Versant Ventures

Jerel Davis is a Managing Director of Versant Ventures based in Vancouver, Canada. Since joining Versant in 2011, he has been instrumental in establishing the company’s presence in Canada and has been involved in launching and investing in a number of Versant’s portfolio companies including BlueRock (sale), Crispr (2016 IPO), Inception 4 (sale), Inception 5 (sale), Quanticel (sale), Akero (2019 IPO), Northern (sale), Turnstone, Repare (2020 IPO), Chinook, Ventus, Integral, and VenatoRx. He has focused on company creation, syndicated deals, and creative corporate transactions with multiple pharmaceutical partners including Celgene, Roche, and Bayer. Jerel was promoted to Managing Director at Versant in April 2016.

Jerel holds a B.S. in Mathematics and Biology from Pepperdine University and a Ph.D. in Genetics from Stanford University.

Tentarix Director, Co-Founder of Amplitude Ventures

Allyson Tighe is a Co-Founder and Investor at Amplitude Ventures, a capital catalyst for highly innovative companies at the point of value acceleration. Amplitude is a full-stack venture capital firm employing a unique growth model to build companies with novel science, world-class management teams, and big visions and to scale those companies to breakout potential. With over $500M under management and offices in Montreal, Toronto and Vancouver, Amplitude applies a proven, evidence-based approach to investing in leading precision medicine companies. Allyson is also a former medical device entrepreneur and health technology commercialization advisor committed to advancing great science and passionate about creating, building, and growing world class healthcare companies in Canada. She was previously an investor at the BDC Healthcare Fund where their team managed $270 million in capital with investments in the drug, devices, diagnostics and digital health sectors. Prior to joining BDC, Allyson worked as Business Development Manager at the Centre for Drug Research and Development in Vancouver.

Allyson holds a Bachelor in Science in Genetics and a Masters in Science in Physiology, both from Western University, and an MBA from the Richard Ivey School of Business.

Tentarix Idependent Director

Following a 35-year career at Lilly, Dr. Bumol joined the Allen Institute as Executive Vice President and Director of the Allen Institute for Immunology, which was created by the late philanthropist and Microsoft co-founder Paul G. Allen. At Lilly, Dr. Bumol was the Senior Vice President of Biotechnology and Immunology Research and the Site Head of Lilly’s Biotechnology Center in San Diego. Dr. Bumol’s teams and collaborators advanced over 100 molecules into clinical development, including Trulicity® (dulaglutide), Taltz® (ixekizumab), Emgality® (galcanezumab), Mounjaro® (terzepatide) and mirikizumab. Through strategic alliances, he and his teams also helped develop and support Reopro® (abciximab) with Centocor as well as Olumiant® (baricitinib) with Incyte. Dr. Bumol has over 50 publications and reviews and eight issued U.S. patents. He earned a Ph.D. at the University of Minnesota and received the Damon Runyon-Walter Winchell Cancer Research Fellowship for his postdoctoral research in the Department of Molecular Immunology at Scripps Clinic and Research Foundation in La Jolla, California.

Tentarix Director, CSO of Innvative Tareing Solutions

Paul Kang is a founder of Tentarix and has been involved in the development and application of antibody generation technologies for over 20 years, with time at ImmGenics Pharmaceuticals, Abgenix Inc., and Amgen Inc. Paul has played an instrumental role in the development and deployment of novel first-in-class antibody discovery technologies, including ImmGenics’ SLAM technology (Selected Lymphocyte Antibody Method) and Abgenix’s XenoMouse Technology, which was subsequently acquired by Amgen. At Amgen, Paul oversaw Amgen British Columbia’s Preclinical In Vitro Cellular Assay and In Vivo Pharmacology research teams, whose primary responsibilities were the screening and characterization of XenoMouse-derived antibodies. After leaving Amgen, Paul was a co-founder of Innovative Targeting Solutions (ITS). As CSO of ITS, Paul oversaw the advancement of the company’s HuTARG protein engineering platform and the company’s six pharma collaborations. Paul is also a co-founder of A2 Biotherapeutics and an inventor on over 15 pending or granted patents.

Paul holds a B.S. from Simon Fraser University.